Filing Flows › Protalix BioTherapeutics (PLX) › Operating margin
Protalix BioTherapeutics (PLX) operating margin by quarter
Protalix BioTherapeutics' operating margin was 23.5% in Q2 2026 (second quarter 2026), -39.2 pts from Q1 2026. Over the last 5 quarters it ranged from 7.5% (Q2 2025) to 62.7% (Q1 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 23.5% | -39.2 pts | +16.0 pts |
| Q1 2026 | 62.7% | +50.7 pts | — |
| Q3 2025 | 11.9% | +4.5 pts | — |
| Q2 2025 | 7.5% | -32.1 pts | — |
| Q4 2024 | 39.6% | — | — |
Q2 2026 at a glance
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' operating margin?
Protalix BioTherapeutics' operating margin was 23.5% in Q2 2026 (second quarter 2026), -39.2 pts from Q1 2026.
How has Protalix BioTherapeutics' operating margin changed?
Over the last 5 quarters it ranged from 7.5% (Q2 2025) to 62.7% (Q1 2026).
Q2 2026 results → · How Protalix BioTherapeutics makes money →